Menzel Garry E
SEC insider (Form 3/4/5 filer). CIK 0001556064. Director at Black Diamond Therapeutics, Inc. (BDTX) and 1 other issuer. 3 reported Form 4/5 transactions since Sep 2024; latest on Jun 26, 2026. Located in CAMBRIDGE, MA.
Companies Menzel Garry E has filed insider reports for
- Black Diamond Therapeutics, Inc. (BDTX): Director
- Stoke Therapeutics, Inc. (STOK): Director
Menzel Garry E
CIK: 0001556064
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jun 26, 2026BDTX
Black Diamond Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
40K shares- - Jun 12, 2025BDTX
Black Diamond Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
30.6K shares- - Jun 3, 2025STOK
Stoke Therapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
29.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 26, 2026 |  BDTX Black Diamond Therapeutics, Inc. | Award Stock Option (Right to Buy) | 40,000 | - | - | Direct |
| Jun 12, 2025 | BDTX Black Diamond Therapeutics, Inc. | Award Stock Option (Right to Buy) | 30,550 | - | - | Direct |
| Jun 3, 2025 |  STOK Stoke Therapeutics, Inc. | Award Director Stock Option (Right to Buy) | 29,747 | - | - | Direct |
1-3 of 3 transactions